| scholarly article | Q13442814 |
| P2093 | author name string | Hideho Okada | |
| Pawel Kalinski | |||
| P2860 | cites work | Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models | Q21245475 |
| Cancer immunotherapy: moving beyond current vaccines | Q24548229 | ||
| Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution | Q24679240 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| Type, density, and location of immune cells within human colorectal tumors predict clinical outcome | Q28131662 | ||
| Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon | Q28244215 | ||
| DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27 | Q28285583 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| Interleukin-12 and the regulation of innate resistance and adaptive immunity | Q29614602 | ||
| Central memory and effector memory T cell subsets: function, generation, and maintenance | Q29615097 | ||
| Retinoic acid imprints gut-homing specificity on T cells | Q29619126 | ||
| Taking dendritic cells into medicine | Q29619243 | ||
| Immunosuppressive strategies that are mediated by tumor cells | Q29636247 | ||
| CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease | Q30435000 | ||
| Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. | Q33188469 | ||
| Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer | Q33470429 | ||
| Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. | Q33744525 | ||
| T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal | Q33774232 | ||
| The role of COX-2 in intestinal cancer | Q33834299 | ||
| Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. | Q33855405 | ||
| The role of chemokine receptors in primary, effector, and memory immune responses | Q33932742 | ||
| Effector memory T cells, early metastasis, and survival in colorectal cancer | Q33992461 | ||
| Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines | Q34009362 | ||
| Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia | Q34011555 | ||
| Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. | Q34066925 | ||
| Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells | Q34067493 | ||
| Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells | Q34103579 | ||
| Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. | Q34114993 | ||
| Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression | Q34118755 | ||
| Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells | Q34141893 | ||
| Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells | Q34147162 | ||
| Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation | Q39853571 | ||
| Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. | Q40005494 | ||
| Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma | Q40016466 | ||
| Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. | Q40017255 | ||
| IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. | Q40134661 | ||
| Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. | Q40272726 | ||
| Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity | Q40355233 | ||
| Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. | Q40357536 | ||
| EphA2 as a glioma-associated antigen: a novel target for glioma vaccines | Q40365151 | ||
| Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. | Q40455900 | ||
| Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. | Q40701835 | ||
| CD8 T Cells Inhibit IgE Via Dendritic Cell IL-12 Induction That Promotes Th1 T Cell Counter-Regulation | Q40761672 | ||
| Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma | Q40789183 | ||
| Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors | Q41649620 | ||
| ELAM-1 is an adhesion molecule for skin-homing T cells | Q41694765 | ||
| Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. | Q41968893 | ||
| Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro | Q42022012 | ||
| Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma | Q42482085 | ||
| Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma | Q42741820 | ||
| Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients | Q42742001 | ||
| CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal | Q42834238 | ||
| Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo | Q42837010 | ||
| Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function | Q43442797 | ||
| Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells | Q43531952 | ||
| Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice | Q43579164 | ||
| Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells | Q43582877 | ||
| Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer | Q43615371 | ||
| Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases | Q43874383 | ||
| Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets | Q44083646 | ||
| Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy | Q44319954 | ||
| Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma | Q44383579 | ||
| Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism | Q44555982 | ||
| Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans | Q45221904 | ||
| Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines | Q45710841 | ||
| Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. | Q45876914 | ||
| Immunotherapy for prostate cancer: walk, don't run. | Q45918453 | ||
| Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy | Q46468994 | ||
| Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine | Q46480176 | ||
| Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions | Q46516332 | ||
| Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells | Q46578425 | ||
| Relationship of lymphocyte invasion and survival of brain tumor patients | Q48162265 | ||
| Tumor-specific killer cells in paraneoplastic cerebellar degeneration | Q48353734 | ||
| Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. | Q48582022 | ||
| Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. | Q51610481 | ||
| CD44high memory CD8 T cells synergize with CpG DNA to activate dendritic cell IL-12p70 production | Q51955847 | ||
| Dendritic cells support sequential reprogramming of chemoattractant receptor profiles during naive to effector T cell differentiation | Q52007148 | ||
| Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin | Q52013140 | ||
| Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. | Q52025690 | ||
| Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells | Q52066142 | ||
| Differential expression of homing-associated adhesion molecules by T cell subsets in man | Q52104629 | ||
| Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. | Q52905310 | ||
| Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer | Q53362101 | ||
| Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells | Q54102042 | ||
| Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood | Q54451826 | ||
| Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function | Q56880717 | ||
| Variations in the Distribution, Frequency, and Phenotype of Langerhans Cells During the Evolution of Malignant Melanoma of the Skin | Q56904146 | ||
| A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients | Q57570360 | ||
| Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state | Q57779701 | ||
| Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients | Q61775079 | ||
| Infiltrated Neutrophils Acquire Novel Chemokine Receptor Expression and Chemokine Responsiveness in Chronic Inflammatory Lung Diseases | Q62555626 | ||
| Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses | Q64380569 | ||
| Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes | Q71612614 | ||
| Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells | Q73035410 | ||
| Dendritic cells transfected with interleukin‐12 and pulsed with tumor extract inhibit growth of murine prostatic carcinoma in vivo | Q73311326 | ||
| Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer | Q73311980 | ||
| Advanced neuroblastoma impairs dendritic cell function in adoptive immunotherapy | Q73460728 | ||
| Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction | Q73709048 | ||
| Clinical significance of defective dendritic cell differentiation in cancer | Q73803370 | ||
| A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells | Q73821429 | ||
| Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions | Q74179201 | ||
| Interleukin-12-gene transduction makes DCs from tumor-bearing mice an effective inducer of tumor-specific immunity in a peritoneal dissemination model | Q74268509 | ||
| Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells | Q74310288 | ||
| Minimal recruitment and activation of dendritic cells within renal cell carcinoma | Q74418862 | ||
| Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo | Q77323598 | ||
| High-level IL-12 production by human dendritic cells requires two signals | Q77658954 | ||
| The importance of defining the paraneoplastic neurologic disorders | Q77856125 | ||
| Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12 | Q78175477 | ||
| Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro | Q79467943 | ||
| The promise of cancer vaccines | Q80038678 | ||
| Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells | Q80201760 | ||
| alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity | Q80516665 | ||
| Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors | Q80579967 | ||
| The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization | Q80843163 | ||
| The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase | Q81000005 | ||
| Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses | Q81455935 | ||
| Therapeutic cancer vaccines | Q82495300 | ||
| Rethinking therapeutic cancer vaccines | Q84501330 | ||
| Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells | Q34211233 | ||
| Retinoic acid: an educational "vitamin elixir" for gut-seeking T cells | Q34358924 | ||
| Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines | Q34408293 | ||
| IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells | Q34430450 | ||
| Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype | Q34438703 | ||
| Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer | Q34543188 | ||
| Influence of effector molecules on the CD8(+) T cell response to infection | Q34612543 | ||
| The role of chemokines in melanoma tumor growth and metastasis | Q34680888 | ||
| How dendritic cells and microbes interact to elicit or subvert protective immune responses | Q34712641 | ||
| Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. | Q34808316 | ||
| All in the head: obstacles for immune rejection of brain tumours | Q34842204 | ||
| Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice | Q34983932 | ||
| Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease | Q35051201 | ||
| The use of dendritic cells in cancer immunotherapy | Q35084257 | ||
| Tumor Escape from Immune Response: Mechanisms and Targets of Activity | Q35554921 | ||
| Dendritic-cell control of pathogen-driven T-cell polarization | Q35597117 | ||
| Dendritic cell immunotherapy: mapping the way. | Q35762464 | ||
| Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors | Q35794641 | ||
| Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors | Q35832333 | ||
| Cancer immunotherapy: a treatment for the masses | Q35833153 | ||
| The critical role of type-1 innate and acquired immunity in tumor immunotherapy | Q35911850 | ||
| Chemoattractants and their receptors in homeostasis and inflammation | Q35931538 | ||
| Tumor-host immune interactions and dendritic cell dysfunction | Q35941603 | ||
| Mechanisms and functional significance of tumour-induced dendritic-cell defects | Q35968465 | ||
| Helper role of NK cells during the induction of anticancer responses by dendritic cells | Q35988425 | ||
| The role of chemokines in the biology and therapy of breast cancer. | Q36027908 | ||
| Dendritic-cell-based therapeutic vaccination against cancer | Q36070700 | ||
| Migration of dendritic cell based cancer vaccines: in vivo veritas? | Q36070704 | ||
| Dendritic cells as therapeutic vaccines against cancer | Q36085614 | ||
| Role of chemokines in tumor growth | Q36120825 | ||
| Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice | Q36228938 | ||
| Dendritic cell dysfunction in cancer: a mechanism for immunosuppression | Q36262281 | ||
| Natural killer-dendritic cell cross-talk in cancer immunotherapy | Q36273386 | ||
| Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen | Q36357871 | ||
| Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines | Q36366108 | ||
| Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. | Q36371035 | ||
| Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells | Q36371345 | ||
| In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. | Q36375533 | ||
| Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues | Q36402630 | ||
| Regulatory T cells, tumour immunity and immunotherapy | Q36430144 | ||
| Making sense of inflammation, epigenetics, and memory CD8+ T-cell differentiation in the context of infection | Q36528995 | ||
| Inflaming the CD8+ T cell response. | Q36543883 | ||
| Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity. | Q36563563 | ||
| The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. | Q36617478 | ||
| Altered maturation of peripheral blood dendritic cells in patients with breast cancer. | Q36671247 | ||
| Reversal of tumor-mediated immunosuppression | Q36718968 | ||
| The adaptive immunologic microenvironment in colorectal cancer: a novel perspective | Q36749070 | ||
| Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines | Q36751608 | ||
| Cancer vaccines: moving beyond current paradigms | Q36868126 | ||
| Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). | Q36909396 | ||
| Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis | Q36934781 | ||
| Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. | Q37001451 | ||
| Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer | Q37038179 | ||
| Tumour immunity: effector response to tumour and role of the microenvironment | Q37085136 | ||
| Paradigm shifts in cancer vaccine therapy. | Q37122893 | ||
| Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells | Q37139993 | ||
| Immunotherapeutic approaches for glioma | Q37267793 | ||
| Cancer immunotherapy by dendritic cells | Q37272237 | ||
| Inflammatory signals in dendritic cell activation and the induction of adaptive immunity | Q37361473 | ||
| The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis | Q37374958 | ||
| IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit | Q37408970 | ||
| Generation and maintenance of memory CD4(+) T Cells | Q37413769 | ||
| Emerging therapies in castrate-resistant prostate cancer | Q37442526 | ||
| Homing receptors and vascular addressins: cell adhesion molecules that direct lymphocyte traffic. | Q38680338 | ||
| Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function | Q39824406 | ||
| P433 | issue | 3 | |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 173-182 | |
| P577 | publication date | 2010-04-20 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Seminars in Immunology | Q15762658 |
| P1476 | title | Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors | |
| P478 | volume | 22 |
| Q34292741 | Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells |
| Q36821243 | CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy |
| Q35167582 | Cytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response |
| Q38691953 | Dendritic cell based vaccination strategy: an evolving paradigm |
| Q40875816 | Dendritic cell immunotherapy for brain tumors. |
| Q85052740 | Dendritic cells in cancer immunotherapy |
| Q34649397 | Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. |
| Q41520681 | Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? |
| Q61656595 | Differential effects of monophosphoryl lipid A and cytokine cocktail as maturation stimuli of immunogenic and tolerogenic dendritic cells for immunotherapy |
| Q83513978 | Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine |
| Q38261273 | Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. |
| Q37891886 | Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments |
| Q38148774 | Exploiting dendritic cells in the development of cancer vaccines |
| Q57824330 | Further clinical advancement of dendritic cell vaccination against ovarian cancer |
| Q92282719 | Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies |
| Q37211699 | Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients |
| Q36243536 | Immunotherapy of cancer in 2012 |
| Q34716748 | In Vivo Intracellular Oxygen Dynamics in Murine Brain Glioma and Immunotherapeutic Response of Cytotoxic T Cells Observed by Fluorine-19 Magnetic Resonance Imaging |
| Q34666875 | Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo |
| Q34216915 | Langerhans Cells and T Cells Sense Cell Dysplasia in Oral Leukoplakias and Oral Squamous Cell Carcinomas – Evidence for Immunosurveillance |
| Q36350299 | Monocytes to functional dendritic cells is often a bridge too far for cancer therapy |
| Q39123677 | Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment. |
| Q45967667 | OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity. |
| Q21245758 | Oncolytic viruses as therapeutic cancer vaccines |
| Q27014714 | Overlapping, Additive and Counterregulatory Effects of Type II and I Interferons on Myeloid Dendritic Cell Functions |
| Q26765345 | Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination |
| Q55003884 | Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies. |
| Q64103056 | The clinical application of cancer immunotherapy based on naturally circulating dendritic cells |
| Q92922634 | Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update |
| Q28397609 | Therapeutic cancer vaccines and combination immunotherapies involving vaccination |
Search more.